Results 201 to 210 of about 867,008 (306)

Consumer Behavior Toward Health‐Related Mobile Applications: A Hybrid Review and Future Agenda

Journal of Consumer Behaviour, EarlyView.
ABSTRACT Mobile health (MH) has the potential to address many consumer challenges, but consumer responses to it remain varied. In this regard, the consumer's perspective on MH is becoming increasingly attractive to academia and business. This review aims to synthesize and analyze 103 studies from 2010 to 2024 using the Scientific Procedures and ...
Omer Faruk Celebi, Ebru Tumer, Nilsah Cavdar Aksoy, Alev Kocak Alan   +3 more
wiley   +1 more source

The genetic architecture of HIV-1 virulence. [PDF]

Virus Evol
Blanquart F, Wymant C, Hall M, Power R, Golubchik T, Gall A, de Cesare M, Macintyre-Cockett G, Bakker M, Bezemer D, Gabrielaite M, Ong SH, Kendall M, Sauter R, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Marvig RL, Meixenberger K, Meyer L, van Sighem A, Bonsall D, van der Valk M, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C.   +32 more
europepmc   +1 more source

Shedding Light on Synthetic Autocatalysis: From Conventional Closed‐Shell Chemistries to Overlooked Open‐Shell Occurrences

Chemistry – A European Journal, EarlyView.
Why add another catalyst when the product itself holds the power to catalyze its own formation? Autocatalysis in synthetic chemistry enhances reaction efficiency and uncovers novel catalytic behavior across both closed‐shell and open‐shell systems, expanding reactivity and enabling innovative design strategies.
Jaspreet Kaur, Joshua P. Barham
wiley   +1 more source

An immunofluorescence microscopy assay to discriminate distinct expression patterns of HIV-1 Gag and Nef proteins in HIV-1 provirus-harboring cells. [PDF]

PLoS One
Wiscovitch-Russo R, Sui H, Smith M, Imamichi H, Lane HC, Imamichi T.   +5 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Social Perceptions of Protection against HIV Infection among Female Street Prostitutes.

Iranian Journal of Public Health, 2014
Saeedeh Moayedi-Nia, Mohsen Naserirad, Banafshe Moradmand Badie, Asiye Ghorbani, Minoo Mohraz   +4 more
doaj  

HIV-1 subtype diversity trends in a Northern California cohort. [PDF]

AIDS
Tao K, Tzou PL, Sahoo MK, Hare CB, Pinsky BA, Shafer RW.   +5 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Harmonizing HIV-1 RNA laboratory measurements in a longitudinal cohort collaboration. [PDF]

Am J Epidemiol
Lee JS, Humes E, Haw NJL, Hogan B, Zheng C, Coburn S, Lesko CR, Lang R, Gill MJ, Horberg M, Silverberg MJ, Palella FJ, Delaney JA, Rebeiro PF, Sterling T, Rodriguez-Barradas M, Marconi VC, Yendewa GA, Klein MB, Moore R, Althoff KN, Research And Design Na-Accord OBOTNAACCO.   +21 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source